Please login to the form below
Therapeutic vaccines
This page shows the latest Therapeutic vaccines news and features for those working in and with pharma, biotech and healthcare.
EU secures 405 million doses of CureVac’s COVID-19 vaccine
CureVac’s candidate, like other investigational vaccines from Pfizer and BioNTech and Moderna, uses mRNA technology, which is a relatively new research area. ... The hope is that by using mRNA technology to develop vaccines and therapeutic treatments,
Latest news
-
CureVac reveals early data for mRNA-based COVID-19 vaccine candidate
mRNA technology has been in the spotlight during the race to develop a COVID-19 vaccine, with a number of companies utilising this research area to develop innovative vaccines for the ... The hope is that by using mRNA technology to develop vaccines and
-
GSK agrees on 10% equity stake in mRNA specialist CureVac
collaboration focused on the development of mRNA-based vaccines and monoclonal antibodies (mAbs). ... The hope is that by using mRNA technology to develop vaccines and therapeutic treatments, specific proteins and antigens can be produced by the body’s
-
J&J catches up to Merck, files Ebola vaccine in Europe
said Johan Van Hoof, global therapeutic area head, vaccines and managing director, Janssen vaccines &prevention. ... Meanwhile, J&J and Merck are now looking to gain official regulatory approvals for their Ebola vaccines with global healthcare agencies.
-
Bayer takes control of BlueRock stem cell joint venture
In April, Leaps by Bayer made an undisclosed investment in US-based biotech Khloris Biosciences, which specialises in using iPSCs as prophylactic and therapeutic vaccines, using them as a vehicle to
-
AMR research 'under threat' due to lack of economic incentives
The AMR Industry Alliance said urgent action is needed to address economic challenges to R&D in areas such as antibiotics, vaccines, diagnostics and therapeutic agents.
More from news
Approximately 0 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Switzerland: a life sciences hub
A partial revision to the Swiss Patents Act and its implementing provisions came into force on 1 January 2019, together with an ordinary revision of the Therapeutic Products Act. ... For example, over the last five years, Lundbeck acquired Prexton
-
Biotech profile: Tom Evans, CEO, Vaccitech.
You have a broad pipeline of candidates, including therapeutic vaccines, such as your vaccine for prostate cancer in phase 1. ... How big a role do you think therapeutic vaccines will play in future cancer treatment?
-
Cancer immunotherapy: What's on the horizon?
Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... Vaccines. While the first therapeutic cancer vaccines have reached the market, eg Dendreon’s Provenge and
-
Deal Watch table for January 2015
Exclusive licence. 522. AC Immune/ Janssen. To develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease. ... 3 year research collaboration and exclusive licence. 509. Neuropore Therapies/UCB. To develop
-
Pharma deals during July 2014
The deal brings to Mylan a portfolio of over 100 specialty and branded generic products in five major therapeutic areas (cardio-metabolic, gastrointestinal, anti-infective/respiratory, CNS/pain and women's ... Baxter forecasts that its revenues from
More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Neon Therapeutics taps Dr Richard Gaynor for R&D leadership role
At Cambridge, US-based Neon he will be tasked with guiding the immuno-oncology company's research programmes, which are focused on developing neoantigen-based therapeutic vaccines and T cell therapies.
-
Bionor names executive management team additions
Together, they bring a wealth of experience to advance therapeutic vaccines for Bionor, and specifically will add operational strength to get our HIV functional cure approach advanced to patients and the
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Novo Nordisk to buy Dicerna Pharmaceuticals for $3.3bn
- US demand for COVID-19 antibody treatments rising fast
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Novo Nordisk to buy Dicerna Pharmaceuticals for $3.3bn
- AstraZeneca/Moderna’s mRNA treatment for heart failure looks promising
- First trial of a vaccine against Alzheimer’s launches
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
PMHub
M3 (EU)
M3 is the world’s largest network of verified doctors with over 6 million members across key markets; our closed and...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
